A recent study by Japanese investigators also assessing the clinical utility of serum fucosylated hemopexin in HCC, LC and chronic hepatitis subjects concluded that the glycoprotein could be used as a biomarker potentially indicative of a hypercarcinogenic liver [55]. Here, HPX is linked to chronic hepatitis.